Literature DB >> 15264244

Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.

M B Gretzer1, D W Chan, C L van Rootselaar, J M Rosenzweig, S Dalrymple, L A Mangold, A W Partin, R W Veltri.   

Abstract

BACKGROUND: Surface enhanced laser desorption and ionization-time-of-flight (SELDI-TOF) is an evolving proteomic technology for improving biomarker discovery that allows for rapid and sensitive analysis of complex protein mixtures generated from body fluids, cells, and/or tissues. SELDI--based profiling identifies unique, differentially expressed proteins relating to specific cancer-related disease states. We utilized SELDI-TOF following pre-processing with molecular separation and chemical fractionation of cell membrane extracts from three Dunning rat prostate cancer cell lines of varying metastatic potential to search novel proteins that are differentially expressed.
METHODS: Dunning rat cell sublines of variable (%) metastatic potential; G (0%), AT-1 (20%), and Mat-Ly-Lu (100%) were cultured in two different laboratories. Cell lysis was performed in a homogenation buffer (320 mM sucrose/50 mM Tris/0.5 mM PSMF) using Dounce homogenation. After centrifugation, the membrane pellet was washed 2x and then solublized in 2% CHAPS/8 M urea. This sample was further processed using positive pressure molecular ultrafiltration at 30 kDa or precipitation with 50% ammonium sulfate. Next, each sample was applied to an IMAC3-Ni ProteinChip (Ciphergen Biosystems, Freemont, CA) and analyzed using Ciphergen's Protein Biology System with protein peak analysis software.
RESULTS: SELDI-TOF analysis differentiated the three Dunning rat cell sublines based upon protein concentration normalized profiles between 5,000 and 20,000 Da. The preparations from the three cells lines showed clear differences when the extracts from the metastatic sublines (AT-1 and MLL) were compared to the benign subline (G) for proteins with molecular weights of 9 kDa (decrease), 12 kDa (significant decrease), 14 kDa (decrease), and 17 kDa (significant gain). After pre-processing extracts with ammonium sulfate and molecular ultrafiltration, the molecular profile changes from one subline to the next became more apparent. Our results were reproducible using multiple runs including from Dunning cells cultured in a separate laboratory, and using different lots of SELDI ProteinChips.
CONCLUSIONS: The application of SELDI-TOF to a series of Dunning rat prostate cancer cell lines illustrated apparent changes in protein profiles among the three cell lines with known differences in metastatic biologic activity. SELDI-TOF identified four reproducible changes in protein expression in the AT1 and MLL metastatic cell sublines. Three of the expression changes were manifested as decreases, but one protein (17 kDa) was over-expressed in the AT1 and MLL cell lines. Emphasis will be placed on the isolation, purification, and characterization of the 17 kDa over-expressed protein and its potential role in PCa metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15264244     DOI: 10.1002/pros.20066

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Best of the 2003 AUA Annual Meeting: Highlights from the 2003 Annual Meeting of the American Urological Association, April 26-May 1, 2003, Chicago, IL.

Authors: 
Journal:  Rev Urol       Date:  2003

2.  SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis.

Authors:  Lei Cheng; Liang Zhou; Lei Tao; Ming Zhang; Jiefeng Cui; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

3.  Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.

Authors:  Carl Wibom; Lina Mörén; Mads Aarhus; Per Morten Knappskog; Morten Lund-Johansen; Henrik Antti; A Tommy Bergenheim
Journal:  J Neurooncol       Date:  2009-04-07       Impact factor: 4.130

4.  The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.

Authors:  Kemal Atahan; Hakan Küpeli; Serhat Gür; Türkan Yiğitbaşı; Yasemin Baskın; Seyran Yiğit; Mehmet Deniz; Atilla Cökmez; Ercüment Tarcan
Journal:  Int J Med Sci       Date:  2011-02-12       Impact factor: 3.738

5.  Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS).

Authors:  Huixiao Hong; Yvonne Dragan; Joshua Epstein; Candee Teitel; Bangzheng Chen; Qian Xie; Hong Fang; Leming Shi; Roger Perkins; Weida Tong
Journal:  BMC Bioinformatics       Date:  2005-07-15       Impact factor: 3.169

Review 6.  Application of proteomics in the study of tumor metastasis.

Authors:  Zhen Cai; Jen-Fu Chiu; Qing-Yu He
Journal:  Genomics Proteomics Bioinformatics       Date:  2004-08       Impact factor: 7.691

7.  Enhanced Detection of Low-Abundance Human Plasma Proteins by Integrating Polyethylene Glycol Fractionation and Immunoaffinity Depletion.

Authors:  Zhao Liu; Songhua Fan; Haipeng Liu; Jia Yu; Rui Qiao; Mi Zhou; Yongtao Yang; Jian Zhou; Peng Xie
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.